Efficacy of new retinoids in the prevention of mammary cancers and correlations with short-term biomarkers

Carcinogenesis

Volumn 27, Issue 6, 2006, Pages 1232-1239

  Grubbs, Clinton J ^a   Lubet, Ronald A ^d   Atigadda, Venkatram R ^b   Christov, Konstantin ^e   Deshpande, Anil M ^b   Tirmal, Vivek ^b   Xia, Gang ^b   Bland, Kirby I ^b   Eto, Isao ^c   Brouillette, Wayne J ^b   Muccio, Donald D ^b  

^a University of Alabama at Birmingham   (United States)

^b National Cancer Institute ^*  (United States)

^c University of Alabama at Birmingham   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 METHYL UAB 30; ALITRETINOIN; BEXAROTENE; BIOLOGICAL MARKER; METHYLNITROSOUREA; RETINOID; RETINOID DERIVATIVE; RETINOID X RECEPTOR; TRIACYLGLYCEROL; UAB 112; UAB 20; UAB 30; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BINDING SITE; BREAST CANCER; CELL PROLIFERATION; CHEMOPROPHYLAXIS; COMPUTER MODEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SCREENING; FEMALE; LIGAND BINDING; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTICARCINOGENIC AGENTS; FEMALE; LIPIDS; MAMMARY NEOPLASMS, ANIMAL; MODELS, CHEMICAL; MOLECULAR CONFORMATION; PROTEIN STRUCTURE, TERTIARY; RATS; RATS, SPRAGUE-DAWLEY; RETINOID X RECEPTOR ALPHA; RETINOIDS; TRIGLYCERIDES; TUMOR MARKERS, BIOLOGICAL;

EID: 33745600377     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgi308     Document Type: Article

References (29)

1. Dunn,B.K. and Ford,L.G. (2001) From adjuvant therapy to breast cancer prevention: BCPT and STAR. Breast J., 7, 144-157.
2. Lubet,R.A., Steele,V.E., DeCoster,R., Bowden,C., You,M., Juliana,M.M., Eto,I., Kelloff,G.J. and Grubbs,C.J. (1998) Chemopreventive effects of the aromatase inhibitor vorozole (R83842) in the methylnitrosourea-induced mammary cancer model. Carcinogenesis, 19, 1345-1351.
3. Pappas,S.G. and Jordon,V.C. (2002) Chemoprevention of breast cancer: current and future prospects. Cancer Metastasis Rev., 21, 311-321.
4. Gottardis,M.M., Bischoff,E.D., Shirley,M.A., Wagoner,M.A., Lamph,W.W. and Heyman,R.A. (1996) Chemoprevention of mammary carcinoma by LGD 1069 (Targretin): An RXR selective ligand. Cancer Res., 56, 5566-5570.
5. Suh,N., Lamph,W.W., Glasebrook,A.L., Grese,T.A., Palkowitz,A.D., Williams,C.R., Risingson,R., Farris,M.R., Heyman,R.A. and Sporn M.B. (2002) Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268. Clin. Cancer Res., 8, 3270-3275.
6. Wu,K., Kim,N-T., Rodriquez,J.L., Hilsenbeck,S.G., Mohsin,S.K., Xu,X-C., Lamph,W.W., Kuhn,J.G., Green,J.E. and Brown,P.H. (2002) Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD 1069. Cancer Epidemiol. Biomarkers Prev., 11, 467-474.
7. Wu,K., Zhang,Y., Xu,C. et al. (2002) The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res., 62, 6376-6380.
8. Bastien,J. and Rochette-Egly,C. (2004) Nuclear retinoid receptors and the transcription of retinoid-target genes. Gene, 328, 1-16.
9. Ahuja,H.S., Szanto,A., Nagy,L. and Davies,P.J. (2003) The retinoid X receptor and its ligands: Versatile regulators of metabolic function, cell differentiation and cell death. J. Biol. Regul. Homeost. Agents, 17, 29-45.
10. Farol,L.T. and Hymes,K.B. (2004) Bexarotene: A clinical review. Expert Rev Anticancer Ther., 4, 180-188.
11. Lawerence,J.A., Adamson,P.C., Caruso,R. et al. (2001) Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: Toxicity, pharmacokinetic, and biomarker evaluations. J. Clin. Oncol., 19, 2754-2763.
12. Hill,D.L. and Grubbs,C.J. (1992) Retinoids and cancer prevention. Annual Rev. Nutr., 12, 161-181.
13. Cope,M.B., Steele,V.E., Lubet,R.A., Eto,I., Julianna,M.M., Hill,D.L. and Grubbs,C.J. (2004) Efficacy of 9-cis-retinoic acid and N-(4-hydroxyphenyl)retinamide alone and in combination in mammary cancer prevention. Oncol. Rep., 11, 465-469.
14. Grubbs,C.J., Hill,D.L., Bland,K.I., Beenken,S.W., Lin,T.H., Eto,I., Atigadda,V.R., Vines,K.K., Brouillette,W.J. and Muccio,D.D. (2003) 9cUAB30, an RXR specific retinoid, and/or tamoxifen in the prevention of methylnitrosourea-induced mammary cancers. Cancer Lett., 201, 17-24,
15. Atigadda,V.R., Vines,K.K., Grubbs,C.J., Hill,D.L., Beenken,S.L., Bland,K.I., Brouillette,W.J. and Muccio,D.D. (2003) Conformationally defined retinoic acid analogues. 5. large-scale synthesis and mammary cancer chemopreventive activity for (2E, 4E, 6Z, 8E)-8-(3′4′-Dihydro- 1′(2′H)-naphthalen-1′-ylidene -3,7-dimethyl-2,4,6-octatrienoic acid (9cUAB30). J. Med. Chem., 46, 3766-3769.
16. Esteva,F.J. and Hortobagyi,G.N. (2004) Prognostic molecular markers in early breast cancer. Breast Cancer Res., 4, 109-118.
17. Christov,K., Shilkaitis,A., Green,A., Mehta,R.G., Grubbs,C., Kelloff,G. and Lubet,R. (2002) Cellular responses of mammary carcinomas to aromatase inhibitors: Effect of vorozole. Breast Cancer Res. Treat., 60, 117-128.
18. Christov,K., Ikui,A., Shilkaitis,A., Green,A., Yao,R., You,M., Grubbs,C., Steele,V., Lubet,R. and Weinstein,I.B. (2003) Cell proliferation, apoptosis, and expression of cyclin D1 and cyclin E as potential biomarkers in tamoxifen-treated mammary tumors. Breast Cancer Res. Treat,, 77, 253-264.
19. Lubet,R.A., Christov,K., Nunez,N.P., Hursting,S.D., Steele,V.E., Juliana,M.M., Eto,I. and Grubbs,C.J. (2005) Efficacy of Targretin on methylnitrosourea-induced mammary cancers: Prevention and therapy dose-response curves and effects on proliferation and apoptosis. Carcinogenesis, 26, 441-448.
20. Muccio,D.D., Brouillette,W.J., Alam,M., Vaezi,M.F., Sani,B.P., Venepally,P., Reddy,L., Li,E., Norris,A.W., Simpson-Herren,L. and Hill,D.L. (1996). Conformationally defined 6-s-trans-retinoic acid analogs. 3. Structure-activity relationships for nuclear receptor binding, transcriptional activity, and cancer chemopreventive activity. J. Med. Chem., 39, 3625-3635.
21. Peto,J. (1966) The calculation and interpretation of survival cancers. In Buyse,M.E. (ed.) Cancer Clinical Trials: Methods and Practice. Oxford University Press, Oxford, pp. 361-380.
22. Armitage,P. (1966) The chi-square test for heterogeneity of proportion after adjustment for stratification. J. R. Stat. Soc. B, 28, 150-162.
23. McGowan,M.W., Artiss,J.D., Strandbergh,D.R. and Zax B. (1983) A peroxidases-method for the colorimetric determination of serum triglycerides. Clin. Chem., 29, 538-542.
24. Egea,P.F., Mitscheler, A., Rochel,N., Ruff,M., Chambon,P. and Moras,D. (2000) Crystal structure of the human RXRα ligand-binding domain bound to its natural ligand: 9-cis-retinoic acid, EMBO J., 19, 2592-2601.
25. Egea,P.A., Klaholz,B.P. and Moras,D. (2000) Ligand-protein interactions in nuclear receptors of hormones. FEBS Lett., 476, 62-67.
26. Schimerlik,M.I., Peterson,V.J., Hobbs,P.D., Dawson,M.I. and Leid,M. (1999) Kinetic and thermodynamic analysis of 9-cis-retinoic acid binding to the retinoid X receptor. Biochemistry, 38, 6732-6740.
27. Muccio,D.D., Brouillette,W.J., Breitman,T.R. et al. (1998) Conformationally defined retinoic acid analogues. 4. Potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias. J. Med. Chem., 41, 1679-1687.
28. Alam,M., Zhestkov,V., Sani,B.P. et al. (1995) Conformationally defined 6-s-strans-retinoic acid analogs. 2. Selective agonists for nclear receptor binding and transcriptional activity. J. Med. Chem., 38, 2302-2310.
29. Anzano,M.A., Byers,W.W., Smith,J.M., Peer,C.W., Mullen,L.T., Brown,C.C., Roberts,A.B. and Sporn,M.B. (1994) Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res., 54, 4614-4617.